Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States

References

• Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2018 Nov 6 PubMed PMID: 30398671. DOI:10.1002/hep.30297.
   PubMedGoogle Scholar
• Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013 Jun;57(6):2164–2170. PubMed PMID: 23280550; PubMed Central PMCID: PMCPMC3763475.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016 Nov;64(5):1442–1450. PubMed PMID: 27015107; PubMed Central PMCID: PMCPMC5035714.
   PubMed Web of Science ®Google Scholar
• He T, Lopez-Olivo MA, Hur C, et al. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017 Oct;46(8):711–721. PubMed PMID: 28836278.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, He T, Hur C, et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving. Clin Gastroenterol Hepatol. 2017 Jun;15(6):827–837 e8. PubMed PMID: 27650326.
   PubMed Web of Science ®Google Scholar
• Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: world Health Organization. 2018.
   Google Scholar
• Chhatwal J, Chen Q, Ayer T, et al. Hepatitis C retreatment in the Era of direct-acting antivirals: projections in the United States. Aliment Pharmacol Ther. 2018 Apr;47(7):1023–1031.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. 2016 December 6[updated 2018 May 24; cited 2019 Feb 28]; Available from www.hcvguidelines.org
   Google Scholar
• Inc AbbVie. MAVYRET [package insert]. U.S. Food and Drug Administration website. [cited 2019 Feb 28]; Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209394s002lbl.pdf
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
   Google Scholar
• Probst, Adam C.. The effects of selection defaults on the ordering practices of clinicians using an electronic medical record. 2011.
   Google Scholar
• Lang J-P, Melin P, Ouzan D, et al. Pegylated interferon-α2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antivir Ther. 2010;15(4):599.
   PubMed Web of Science ®Google Scholar
• McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making. 2008 PubMed PMID: 18424560;28(4):582–592. Jul-Aug. .
   PubMed Web of Science ®Google Scholar
• Thein -H-H, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100(3):643–651.
   PubMed Web of Science ®Google Scholar
• Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98(3):630–638.
   PubMed Web of Science ®Google Scholar
• Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol. 2012 Jan;27(1):149–157. PubMed PMID: 21679248.
   PubMed Web of Science ®Google Scholar
• Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006 Jul 2006;10(21): 1–113, iii. doi:95-24-03[pii].
   Web of Science ®Google Scholar
• Younossi ZM, Park H, Gordon SC, et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care. 2016 May;22(6 Spec No.):SP205–11. PubMed PMID: 27266950.
   PubMed Web of Science ®Google Scholar
• Wyles D, Weiland O, Yao B. et al. eds. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. The International Liver Congress: Paris. 2018 April 11-15.
   Google Scholar
• Xu F, Moorman AC, Tong X, et al. All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis. 2016 Feb 1;62(3):289–297. PubMed PMID: 26417034.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015 Mar;41(6):544–563. PubMed PMID: 25619871.
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008 Aug;48(2):418–431. PubMed PMID: 18563841.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug;54(2):396–405. PubMed PMID: 21520194; PubMed Central PMCID: PMCPMC3144992.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997 Jul;27(1):201–205. PubMed PMID: 9252096.
   PubMed Web of Science ®Google Scholar
• Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329–337. PubMed PMID: 23460056.
   PubMed Web of Science ®Google Scholar
• Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008 Sep;135(3):821–829. PubMed PMID: 18593587.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012 Aug;56(2):532–543. PubMed PMID: 22271347.
   PubMed Web of Science ®Google Scholar
• Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014 Sep;40(6):657–675. PubMed PMID: 25065960.
   PubMed Web of Science ®Google Scholar
• Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health. 2012 Jan-Feb;15(1 Suppl):S65–71. PubMed PMID: 22265070.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015 Mar 17;162(6):397–406. PubMed PMID: 25775312; PubMed Central PMCID: PMCPMC4435698.
   PubMed Web of Science ®Google Scholar
• Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta-analysis. J Viral Hepat. 2011 Nov;18(11):745–759. PubMed PMID: 21992794.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul;60(1):98–105. PubMed PMID: 24615981; PubMed Central PMCID: PMCPMC4689301.
   PubMed Web of Science ®Google Scholar
• Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep;52(3):833–844. PubMed PMID: 20564351; PubMed Central PMCID: PMC2932862.
   PubMed Web of Science ®Google Scholar
• Saab S, Hunt DR, Stone MA, et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 2010;16(6):748–759.
   PubMed Web of Science ®Google Scholar
• Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013 May 8;61(4):1–117. PubMed PMID: 24979972.
   PubMedGoogle Scholar
• Red Book Online [Internet]. Micromedex 2.0. 2017 [cited 2017 Jul 17]. Available from: http://www.micromedexsolutions.com/home/dispatch
   Google Scholar
• The essential RBRVS: a comprehensive listing of RBRVS (Resource-Based Relative Value Scale) values for CPT and HCHPS codes [Internet]. Optum Insight, Inc; 2017.
   Google Scholar
• McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J managed care pharmacy. 2011 Sep;17(7):531–546. PubMed PMID: 21870894.
   PubMed Web of Science ®Google Scholar
• Gordon SC, Pockros PJ, Terrault NA, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012 Nov;56(5):1651–1660. PubMed PMID: 22610658.
   PubMed Web of Science ®Google Scholar
• Baran RW, Samp JC, Walker DR, et al. Costs and absence of HCV-infected employees by disease stage. J Med Econ. 2015;18(9):691–703. PubMed PMID: 26047262.
   PubMed Web of Science ®Google Scholar
• Puenpatom A, Hull M, McPheeters J et al. eds. Characteristics and prevalence of chronic kidney disease among patients with hepatitis C who are treated with interferon-free direct-acting antiviral regimens. Barcelona, Spain: The International Liver Congress; 2016.
   Google Scholar
• Chhatwal J, Ferrante SA, Brass C, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health. 2013;16(6):973–986.
   PubMed Web of Science ®Google Scholar